COVID-19 Vaccine Introduction Readiness Assessment Tool (VIRAT2), developed by WHO-PAHO, UNICEF, World Bank, Gavi, and other partners is a tool to help prepare countries for the introduction a COVID-19 vaccine.
It provides a roadmap for introduction and a structured framework for countries to self-...monitor their readiness progress against key milestones. It includes an excel template for Ministries of Health to complete with support from partners and PAHO Country Offices.
The VIRAT dashboard helps countries highlight the critical activities and technical areas that should be initiated, continued, or strengthened. Also, it allows PAHO and partners to identify areas where support may be needed and identify alternative forms to mobilize resources.
more
En este apartado se presentan a modo de resumen las principales
conclusiones de este estudio realizado a 360 empresas paraguayas sobre el
impacto económico de la crisis provocada por la COVID-19.
Die Johanniter haben im Rahmen ihrer Aktivitäten im Bereich Flüchtlingshilfe und Integration allgemeine, niedrigschwellige Informationen zum Thema Corona-Impfung in verschiedenen Sprachen bereitgestellt. Diese dienen als Ergänzung zu den offiziellen Informationsmaterialien der Bundeszentrale für... gesundheitliche Aufklärung u.a. Die Informationsblätter wurden in Zusammenarbeit mit dem Ethno-medizinischen Zentrum e.V. Hannover übersetzt und werden bei Bedarf aktualisiert.
Die Informationsblätter sind in zahlreichen Sprachen verfügbar
more
Trata das orientações da vacinação dos grupos de pessoas com comorbidades, pessoas com deficiência permanente e gestantes e puérperas na Campanha Nacional de Vacinação contra a Covid-19, 2021.
27 May 2021
All countries should increase their level of preparedness, alert and response to identify, manage and care for new cases of COVID-19. Countries should prepare to respond to different public health scenarios, recognizing that there is no one-size-fits-all approach to managing cases and o...utbreaks of COVID-19. Each country should assess its risk and rapidly implement the necessary measures at the appropriate scale to reduce both COVID-19 transmission and economic, public and social impacts.
more
This report provides an overview of the progress in the roll-out of COVID-19 vaccines in adults (aged 18 years and above) across EU/EEA Member States. It presents the number of vaccine doses distributed by manufacturers to each Member State for the different approved vaccines and the number of first..., second or unspecified doses administered to adult individuals overall, by age group and other selected target groups including healthcare workers (HCW) and residents in long-term care facilities (LTCF).
more
26 March 2021
If you have already had COVID-19 do you still need both doses of the vaccine? Do these vaccines protect you against infection? Do they protect us against variants? WHO’s Dr Katherine O’Brien answers these questions in Science in 5 this week.
Social and behavior change (SBC) professionals have often been tasked to find ways to influence knowledge, attitudes, and practices, about vaccines. Now that the COVID-19 vaccines are becoming available worldwide, renewed emphasis and urgency for SBC efforts arise.
To that end, WHO has offered thre...e factors that play a role in vaccine hesitancy, the first two of which can be addressed by SBC: Complacency: Low perceived risk of vaccine-preventable diseases, and vaccination not deemed necessary. Other life/health issues are a greater priority.
Confidence: Low levels of trust in vaccines, in the delivery system, and in health authorities
Convenience: Barriers related to geographic accessibility, availability, affordability, and acceptability of services
This resource page provide a selection of SBC research, tools, and examples that aid in understanding this issue, especially in light of the recent availability of COVID-19 vaccines and the urgency for immunization worldwide.
more
If you have the choice of more than one vaccine and are wondering which one to take and how to assess the risk of side effects, this episode of Science in 5 with WHO’s Dr Katherine O’Brien is for you.
10 BAGAY OU K A FÈ POU JERE SENTÒM
COVID-19 OU YO L AK AY OU
SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch...ildren. If children with mild or no symptoms transmit the disease, they may act as drivers of transmission within their communities. Understanding symptoms, infectivity and patterns of SARS-CoV-2 transmission in children and adolescents is essential for developing, adapting and improving control measures for COVID-19 across all ages. This is a summary of the current knowledge around SARS-CoV-2 infection acquisition and transmission and COVID-19 disease symptoms in children and adolescents. It aims to inform decisions, based on local contexts, on how to best keep schools, kindergarten and day-care facilities open and what advice to apply to intergenerational mixing.
more
21 May 2021. PACK Home: Information and advice for the home
Available in English, Afrikaans and isiXhosa